Treats asthma. ANDA 202468, held by Aurobindo Pharma. Montelukast Sodium.
As of Nov 21, 2026, ANDA 202468 (Montelukast Sodium), held by Aurobindo Pharma, was first approved by FDA on Aug 3, 2012, with 10 approved supplements and 0 published complete response letters.
Montelukast sodium is a leukotriene receptor antagonist indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE · tablet;oral | Montelukast Sodium | Rx |
| Jan 19, 2022 | Supplement 27Labeling · Standard review | Approved | None posted |
| Aug 14, 2020 | Supplement 24Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 20Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jul 23, 2018 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 8, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 8, 2015 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jun 4, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 13, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 13, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters